Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Peripheral Blood Leukocytes (this asset) | The First Affiliated Hospital of Soochow University | P2 | CCC · 54 |
| Axicabtagene Ciloleucel | Zhejiang Cancer Hospital | P4 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Fludarabine | M.D. Anderson Cancer Center | P4 | BB |
| Etoposide | University of California, Davis | P2/3 | BB |
| Adriamycin | Ruijin Hospital | P3 | BB |
| Prednisone | Ruijin Hospital | P3 | BB |
| Lenalidomide | Ruijin Hospital | P3 | B |
| Golcadomide | Allison Winter | P3 | B |
+41 more in the Large B-Cell Lymphoma cohort
Other indications for Human Peripheral Blood Leukocytes
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P2 | CCC · 51 |
| Malignant Pancreatic Neoplasm | — | Unk | D · 30 |
| Mesothelioma | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Peripheral Blood Leukocytes in Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-peripheral-blood-leukocytes-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →